These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 641719)
1. Autoradiographic distribution studies of 2-14C-fluorouracil following oral or intravenous administration in mice bearing solid sarcoma-180. Shani J; Berman JA; Wolf W J Pharm Sci; 1978 Mar; 67(3):344-7. PubMed ID: 641719 [No Abstract] [Full Text] [Related]
2. Tissue distribution of 5'-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats. Suzuki S; Hongu Y; Fukazawa H; Ichihara S; Shimizu H Gan; 1980 Apr; 71(2):238-45. PubMed ID: 6451469 [TBL] [Abstract][Full Text] [Related]
3. Metabolic fate on 1-hexylcarbamoyl-5-fluorouracil and 5-fluorouracil in mice bearing ascites sarcoma 180. Iigo M; Kuretani K; Hoshi A J Natl Cancer Inst; 1981 Feb; 66(2):345-9. PubMed ID: 6935483 [TBL] [Abstract][Full Text] [Related]
4. Whole body autoradiography of 5-fluorouracil-6-14C in nude mice bearing murine leukemia cells P388. Kishida K; Makita T Radioisotopes; 1983 Sep; 32(9):411-5. PubMed ID: 6665233 [TBL] [Abstract][Full Text] [Related]
5. [Dose, administration time and route and hepatic function-dependent metabolism of 5-FU in mice]. Okamoto M; Takao A; Fujita H Gan To Kagaku Ryoho; 1986 Dec; 13(12):3483-90. PubMed ID: 3789759 [TBL] [Abstract][Full Text] [Related]
6. Whole-body autoradiographic study of the distribution of 195mPt in healthy and tumor-bearing mice treated with labeled cisplatin. Bénard P; Desplanches G; Macquet JP; Simon J Cancer Treat Rep; 1983 May; 67(5):457-66. PubMed ID: 6406060 [TBL] [Abstract][Full Text] [Related]
7. [Studies on the metabolic fate of 5-fluorouracil in the oral administration]. Anada H; Nakamura N; Marumo H Yakugaku Zasshi; 1974 Sep; 94(9):1131-8. PubMed ID: 4476782 [No Abstract] [Full Text] [Related]
8. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Fujii S; Kitano S; Ikenaka K; Shirasaka T Gan; 1979 Apr; 70(2):209-14. PubMed ID: 381088 [TBL] [Abstract][Full Text] [Related]
9. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Fujii S; Ikenaka K; Fukushima M; Shirasaka T Gan; 1978 Dec; 69(6):763-72. PubMed ID: 750271 [No Abstract] [Full Text] [Related]
10. [Studies on the absorption, excretion and distribution of aclacinomycin A: absorption, excretion and distribution of 14C- or 3H-aclacinomycin A in mice, rats and rabbits (author's transl)]. Iguchi H; Seryu Y; Kiyosaki T; Hori S; Tone H; Oki T Jpn J Antibiot; 1980 Feb; 33(2):169-78. PubMed ID: 6929359 [TBL] [Abstract][Full Text] [Related]
11. [Significance of measuring 5-fluorouracil incorporated into RNA of tumor tissue as a parameter for the antitumor activity of 5-fluorouracil and its analogs]. Uchida J; Umeno Y; Takeda S Gan To Kagaku Ryoho; 1992 May; 19(5):677-83. PubMed ID: 1580641 [TBL] [Abstract][Full Text] [Related]
12. Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice. Kreuter J; Hartmann HR Oncology; 1983; 40(5):363-6. PubMed ID: 6684746 [TBL] [Abstract][Full Text] [Related]
13. Distribution of 5-fluorouracil-14C in body tissues after systemic and regional administration in gastric cancer. Min JS; Ban JM; Kim MW; Kim CK; Ryu KJ Yonsei Med J; 1986; 27(3):200-4. PubMed ID: 3798961 [No Abstract] [Full Text] [Related]
14. [Tissue distribution of 14C-tetroxoprim in the rat (author's transl)]. Vergin H Arzneimittelforschung; 1980; 30(2):309-13. PubMed ID: 7378110 [TBL] [Abstract][Full Text] [Related]
15. Relationship between antitumor effect and metabolites of 5-fluorouracil in combination treatment with 5-fluorouracil and guanosine in ascites sarcoma 180 tumor system. Iigo M; Kuretani K; Hoshi A Cancer Res; 1983 Dec; 43(12 Pt 1):5687-94. PubMed ID: 6640523 [TBL] [Abstract][Full Text] [Related]
16. Metabolic studies of 5-fluorouracil. II. Influence of the route of administration on the dynamics of distribution in man. Douglass HO; Mittelman A Cancer; 1974 Dec; 34(6):1878-81. PubMed ID: 4373162 [No Abstract] [Full Text] [Related]
17. Biochemistry of drugs. XXV. Substances with antineoplastic effect. LXIII. Pharmacokinetics of delta-/2-amino-6-hydroxy-3,4-dihydro-4-oxo-5--pyrimidinyl/valeric acid-14C (Damvar-14C) in experimental animals. Francová V; Smolík S; Schlehrová M; Ausková M; Cerný A; Krepelka J; Franc Z; Rezábek K; Semonský M Neoplasma; 1978; 25(4):405-12. PubMed ID: 692802 [TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893). Cohen JL; Irwin LE; Marshall GJ; Darvey H; Bateman JR Cancer Chemother Rep; 1974; 58(5 Pt 1):723-31. PubMed ID: 4609602 [No Abstract] [Full Text] [Related]
19. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Fujii S; Fukushima M; Shimamoto Y; Ohshimo H; Imaoka T; Shirasaka T Jpn J Cancer Res; 1989 Feb; 80(2):173-81. PubMed ID: 2498252 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of SK & F 104864 in experimental animals. II. Tissue distribution]. Fujita H; Okamoto M; Takao A; Abe H; Ishii R; Arase H Gan To Kagaku Ryoho; 1995 Oct; 22(12):1789-92. PubMed ID: 7574811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]